Trump signs 'right-to-try' allowing gravely ill patients to bypass FDA for experimental medicines

by | May 31, 2018

Trump signs 'right-to-try' allowing gravely ill patients to bypass FDA for experimental medicines

by | May 31, 2018

  • President Donald Trump and Vice President Mike Pence had been major supporters of the “right-to-try” legislation, which would bypass drug regulators to give gravely ill patients access to experimental medicines.
  • Proponents say this gives patients hope they would not otherwise have.
  • Critics say the legislation undermines the FDA’s authority to regulate drugs and could leave patients vulnerable to medicines that might not work or may even be harmful.

Read the rest at CNBC.com.

Our Books

latest book lineup.

Related Articles

Related

The Creature From Palestine

The Creature From Palestine

The state is a monster that eats itself, along with individuals within its domain, its spheres of influence, and beyond. Citizens typically don’t perceive this due to the crafty rhetoric generated by the state’s intellectuals. Sometimes the rhetorical machinery breaks...

read more
A Problem From Hell

A Problem From Hell

"Indifference can be just as deadly as direct violence.”- Samantha Power, A Problem From Hell When Raphael Lemkin came up with the word "genocide," he needed a handle for the savagery of mass murder that was occurring in the 1940s and the years before. Unfortunately,...

read more
TGIF: Spooner versus bin Laden

TGIF: Spooner versus bin Laden

In his 2002 letter to America justifying the savage 9/11 attacks, al Qaeda leader Osama bin Laden (himself killed in 2011) wrote after listing his grievances against the U.S. government: You may then dispute that all the above does not justify aggression against...

read more
What Killed the Peace Talks in Ukraine?

What Killed the Peace Talks in Ukraine?

The accepted Western narrative is that, in February 2022, Russia launched a full-scale invasion of Ukraine with the intent of conquering the entire country. But there is a competing narrative that is compelling enough to be worthy of consideration. Following the...

read more